Business
Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the goMolluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them c
About this update from Pelthos Therapeutics Inc.
[{"type":"image","alt":"Channel Therapeutics Corporation","displaySize":"","headline":null,"caption":"Channel Therapeutics Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":179,"url":"https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yWW833l91CiuD7s17uRPhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355","width":300,"height":179}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the go","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children","length":200,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":511,"olType":false},{"type":"text","content":"DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the launch of ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i,ii ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections, a highly contagious viral skin condition.","length":691,"tagName":"p"},{"type":"text","content":"“We believe that the commercial launch of ZELSUVMI marks a significant advancement for patients with molluscum and their caregivers, who previously lacked an at-home treatment option for this burdensome skin infection,” said Scott Plesha, CEO of Pelthos. “We are excite...